CSF3 and small cell lung carcinoma: Etoposide/platinum regimen for SCLC treatment is considered to be associated with 10–20% risk of FN and G-CSF primary prophylaxis is not unambiguously recommended by current guidelines.6–9 We reviewed studies on the basis of which guidelines classified etoposide/platinum regimen for SCLC treatment into the intermediate risk group for FN.